1. Home
  2. ARDX vs HQ Comparison

ARDX vs HQ Comparison

Compare ARDX & HQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

N/A

Current Price

$3.02

Market Cap

797.8M

Sector

Health Care

ML Signal

N/A

Logo Horizon Quantum Holdings Ltd. Class A Ordinary Shares

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$13.45

Market Cap

674.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ARDX
HQ
Founded
2007
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
797.8M
674.1M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
ARDX
HQ
Price
$3.02
$13.45
Analyst Decision
Strong Buy
Buy
Analyst Count
11
2
Target Price
$12.80
★ $20.50
AVG Volume (30 Days)
★ 4.3M
86.6K
Earning Date
11-03-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $2,607,000.00
N/A
Revenue This Year
$19.21
N/A
Revenue Next Year
$28.19
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.96
$8.29
52 Week High
$8.40
$45.00

Technical Indicators

Market Signals
Indicator
ARDX
HQ
Relative Strength Index (RSI) 40.04 46.71
Support Level N/A $13.68
Resistance Level $3.35 $14.43
Average True Range (ATR) 0.12 1.08
MACD 0.01 -0.03
Stochastic Oscillator 25.32 49.55

Price Performance

Historical Comparison
ARDX
HQ

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

Share on Social Networks: